



NDA 21449/S-018

**SUPPLEMENT APPROVAL**

Gilead Sciences, Incorporated  
Attention: Ms. Shalini Gidwani, M.Sc, RAC  
Associate Director, Regulatory Affairs  
333 Lakeside Drive  
Foster City, CA 94404

Dear Ms. Gidwani:

Please refer to your Supplemental New Drug Application (sNDA) dated August 26, 2011, received August 29, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Hepsera (adefovir dipivoxil) 10 mg tablets.

We acknowledge receipt of your amendments dated September 22, 2011 and January 12, 2012.

This "Prior Approval" supplemental new drug application was submitted to update the following sections of the labeling:

- The WARNINGS and PRECAUTIONS and Patient Counseling information in the Package Insert (PI) and the Patient Package Insert (PPI) to include COMPLERA to the list of drugs that should not be administered with HEPSERA;
- The Postmarketing Experience section under Adverse Reactions to include, osteomalacia that is manifested as bone pain and that may contribute to fractures; and
- In the Patient Package Insert under the "What is the most important information I should know about HEPSERA?" to add COMPLERA to the list of nucleoside analog medicines to inform that a patient may be more likely to get lactic acidosis or serious liver problems if a patient is overweight (obese) or have been taking nucleoside analog medicines for a long time.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and patient package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the

revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherly Abraham, Regulatory Project Manager, at (301) 796-3198.

Sincerely,

*{See appended electronic signature page}*

/Kendall Marcus M.D./  
for Debra Birnkrant, M.D.  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SHERLY ABRAHAM  
02/29/2012

KENDALL A MARCUS  
02/29/2012